BlackRock Investment Management’s AtriCure ATRC Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2016
Q4
$2.48M Sell
126,695
-785
-0.6% -$14.2K ﹤0.01% 2078
2016
Q3
$2.02M Buy
127,480
+5,414
+4% +$83.2K ﹤0.01% 2153
2016
Q2
$1.73M Buy
122,066
+18,812
+18% +$287K ﹤0.01% 2226
2016
Q1
$1.74M Buy
103,254
+1,480
+1% +$26K ﹤0.01% 2094
2015
Q4
$2.28M Sell
101,774
-11,333
-10% -$234K ﹤0.01% 1978
2015
Q3
$2.48M Sell
113,107
-16,014
-12% -$400K ﹤0.01% 1917
2015
Q2
$3.18M Buy
129,121
+21,044
+19% +$470K ﹤0.01% 1855
2015
Q1
$2.21M Buy
108,077
+983
+0.9% +$19K ﹤0.01% 1946
2014
Q4
$2.14M Sell
107,094
-277
-0.3% -$4.75K ﹤0.01% 1984
2014
Q3
$1.58M Buy
107,371
+628
+0.6% +$10K ﹤0.01% 2185
2014
Q2
$1.96M Buy
106,743
+40,034
+60% +$666K ﹤0.01% 2084
2014
Q1
$1.25M Buy
66,709
+8,784
+15% +$180K ﹤0.01% 2353
2013
Q4
$1.08M Sell
57,925
-1,309
-2% -$19K ﹤0.01% 2450
2013
Q3
$650K Buy
59,234
+4,897
+9% +$48.3K ﹤0.01% 2743
2013
Q2
$516K Buy
+54,337
New +$473K ﹤0.01% 2834

Other funds holding ATRC

BlackRock Investment Management's ATRC Position: Q4 2016 in Review

BlackRock Investment Management reduced its AtriCure (ATRC) stake by 0.62% in Q4 2016, selling an estimated $14.2K and leaving 126,695 shares worth $2.48M. The position accounts for ﹤0.01% of the portfolio, ranked #2078.

BlackRock Investment Management first reported a position in ATRC in Q2 2013 and has held it in 15 quarters since. The position peaked at $3.18M in Q2 2015. 100 funds tracked by Wall St. Rank hold ATRC as of Q4 2016.

  • BlackRock Investment Management held 126,695 shares of AtriCure worth $2.48M as of Q4 2016.
  • BlackRock Investment Management sold 785 AtriCure shares in Q4 2016, an estimated $14.2K.
  • AtriCure made up ﹤0.01% of BlackRock Investment Management's portfolio in Q4 2016, its #2078 holding.
  • BlackRock Investment Management first reported a position in AtriCure in Q2 2013 and has held it in 15 quarters since.
  • BlackRock Investment Management's AtriCure position peaked at $3.18M in Q2 2015.
  • 100 funds tracked by Wall St. Rank held AtriCure as of Q4 2016.

Based on BlackRock Investment Management's 13F filing for Q4 2016, filed 10 Feb 2017.